Updated Aug 19, 2026
/Moderna soars on cancer vaccine results; Cramer flags Target as profit-taking risk/Nvidia starts H200 deliveries to China while Iran escalation keeps traders on watch/Investors profit from soccer as Premier League club losses skyrocket/Global bond sell-off deepens, long-term government yields hit multi-decade highs/Bill Rasmussen, ESPN founder, dies at 93/Rob Schneider says door remains open for Elle King amid estrangement/Moderna soars on cancer vaccine results; Cramer flags Target as profit-taking risk/Nvidia starts H200 deliveries to China while Iran escalation keeps traders on watch/Investors profit from soccer as Premier League club losses skyrocket/Global bond sell-off deepens, long-term government yields hit multi-decade highs/Bill Rasmussen, ESPN founder, dies at 93/Rob Schneider says door remains open for Elle King amid estrangement

Moderna soars on cancer vaccine results; Cramer flags Target as profit-taking risk

NEW YORK, Aug 19. Moderna shares soared Wednesday after the company reported promising results for its cancer vaccine program, according to CNBC's Jim Cramer, who included both names on his midweek market watchlist. Target, he said, may be a victim of profit-taking.

By Callum Whyte2 min readMRNA
Share

Key takeaways

  • Moderna shares soared Wednesday after the company reported promising results for its cancer vaccine program, according to CNBC's Jim Cramer.
  • Cramer said Target may be a victim of profit-taking, framing the move as technical rather than driven by new fundamental news.
  • Both Moderna and Target were named among Cramer's top 10 stocks to watch Wednesday.
  • Cramer's Moderna summary did not include the trial phase, enrolled patient count, primary endpoint, or comparison arm.
  • The readout's implications for Moderna's cash runway and the program's next development stage were not specified.

NEW YORK, Aug 19. Moderna shares soared Wednesday after the company reported promising results for its cancer vaccine program, according to CNBC's Jim Cramer, who included both names on his midweek market watchlist. Target, he said, may be a victim of profit-taking.

The Moderna rally follows a readout Cramer described as promising. No trial phase, enrolled patient count, primary endpoint, or comparison arm was included in his summary. Each of those details shapes whether a clinical result translates to a durable move: a headline efficacy signal can lift shares quickly, then give way once the full data set reaches investors. The readout's implications for Moderna's cash runway and the program's next development stage were not specified.

Target's appearance on the list carried a different tone. Profit-taking, the pattern in which investors sell a position after accumulated gains, can pressure a stock without any deterioration in underlying business performance. Cramer's framing suggested the move was technical rather than tied to new fundamental news from the company.

Both Moderna and Target were named among Cramer's top 10 stocks to watch in the stock market Wednesday.

Related reading

Frequently asked

Why did Moderna's stock soar on Wednesday?

Moderna shares soared after the company reported promising results for its cancer vaccine program, as described by CNBC's Jim Cramer.

What did Cramer say about Target?

Cramer said Target may be a victim of profit-taking, a technical pattern of investors selling after accumulated gains rather than a response to new fundamental news.

What details were missing from Cramer's Moderna readout?

His summary did not include the trial phase, enrolled patient count, primary endpoint, or comparison arm, nor the implications for Moderna's cash runway or next development stage.

What is profit-taking?

Profit-taking is the pattern in which investors sell a position after accumulated gains, which can pressure a stock without any deterioration in underlying business performance.

Were Moderna and Target on any particular list?

Yes, both were named among Cramer's top 10 stocks to watch in the stock market Wednesday.